Published in Pharma Investments, Ventures and Law Weekly, December 10th, 2006
Net income for the third quarter was negatively impacted by a previously disclosed after-tax charge of approximately $5.4 million, or $0.17 per diluted share, related to the settlement of a lawsuit. Excluding this charge, the Company had net income of $5.5 million, or $0.17 per diluted share. A year earlier, the company had revenue of $163.1 million and net income of $5.0 million, or $0.15 per diluted share in the third quarter of 2005. Cash flow from operations for the third quarter of 2006...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.